The phytohormone salicylic acid (SA) affects plant development and defense responses. Recent 17 studies revealed that SA is also involved in the regulation of sphingolipid metabolism, but the 18 details of this regulation remain to be explored. Here, we use in silico Flux Balance Analysis 19 (FBA) with published microarray data to construct a whole-cell simulation model, including 23 20 pathways, 259 reactions and 172 metabolites, to predict the alterations in flux of major 21 sphingolipid species after treatment with exogenous SA. This model predicts significant changes 22 in fluxes of certain sphingolipid species after SA treatment, changes that likely trigger 23 downstream physiological and phenotypic effects. To validate the simulation, we used isotopic 24 non-stationary metabolic flux analysis to measure sphingolipid contents and turnover rate in 25 Arabidopsis thaliana seedlings treated with SA or the SA analog benzothiadiazole (BTH). The 26 results show that both SA and BTH affect sphingolipid metabolism by not only concentration of 27 certain species, but also the optimal flux distribution and turnover rate of sphingolipid contents.
In the measurement, the natural enrichment of 15 N is relatively constant between samples and 142 treatments.
143
Sphingolipid measurements 144 The plants cultured in labeling medium for the time periods described above were weighed and (Table S1 ). We used biomass as the objective function with the stoichiometries of major 158 components were assigned to their biomass fraction , which comprises major carbohydrates, Flux balance analysis (FBA) 164 Flux balance modeling uses a group of ordinary differential equations. The analysis requires a 165 stoichiometric matrix (S) and a vector (v) built for each reaction, where s ij in the S matrix is the 166 stoichiometric number of the ith metabolite in the jth reaction and v j is the rate of the jth reaction, 167 which is subjected to upper and lower boundary constraints. To reach the in silico "quasi-steady 168 state", the following condition must be fulfilled: Wang et al., 2006) . We assumed that the metabolic flux changed following the 179 same trend as the respective gene expression levels. Therefore, when genes were matched to 180 microarray probes to identify their changes in expression following each treatment, we picked 181 genes that changed more than 1.5-fold in SA-treated plants and more than 2-fold in BTH-treated 182 plants (Table S2) . Then, the adjusted model was recalculated for optimal flux distribution. Model construction for plant sphingolipid metabolism 207 We aimed to explore the changes in plant sphingolipid metabolism in response to SA, by using with poorly-understood dynamics (Varma and Palsson, 1994) , as FBA requires only the 212 stoichiometric relationship in each reaction and the objective function for optimization. In our 213 model, the numbers of molecules of reactants and products in known reactions were obtained 214 from public databases (see Materials and Methods). For the sphingolipid pathways (Table S1 ), 215 those reactions that have not been determined were inferred from their atomic composition or 216 similar reactions. Considering that metabolic balances are mainly affected by a few metabolites 217 that are either in a hub of the network or have high turnover, we picked the sphingolipid species 218 that are relatively abundant or central to the known network (Table 1 ). Since 219 inositolphosphorylceramide and its derivatives are difficult to measure in plants, we excluded 220 those species from our model. isotopic fraction can reach 40-65% ( Figure 1A , 1B and 1D). By contrast, between 9 and 24 h, the 245 labeled fraction constantly rose for the glucosylceramides ( Figure 1C ), which had a lower rate of 246 incorporation than the ceramides or hydroxyceramides. Combined with the concentration of 247 sphingolipids, we calculated the isotopic incorporation rate as shown in Table 2 . (Table 1) . Then, flux balance optimization was performed. Although the glucosylceramides have much larger pool sizes (Table 1) In silico SA and BTH treatments 282 The FBA model hypothesizes the quasi-steady state condition of the target network, and we 283 assume that the sphingolipid pathway will reach at least a transient metabolic balance after SA 284 treatment. Thus, we employed the previous model simulating the resting state to predict the 285 effects of SA treatment. We first used data from microarray analysis of SA-and BTH-treated 286 plants to simulate the effect of these treatments on sphingolipid flux. Sphingolipid-related genes 287 were chosen (see Method) from two microarrays (Table S2 ). LAG 1 HOMOLOG 2 (LOH2), This increase is not specific to fatty acid species, which showed an increase in both trihydroxy 301 long-chain and very-long-chain glucosylceramides (Figure 2) . These results are consistent with 302 the data from 15 N labeled INST MFA (Table 2) . Interestingly, the microarray data showed no 303 significant changes in genes that directly catalyze the pathways in glucosylceramide metabolism, 304 nor any related to glucosylceramide, in response to SA or BTH treatment (Table S2 ). Considering 305 the down-regulation of SBH2 under BTH treatment, we believe that the increase of 306 glucosylceramide metabolism may mainly be induced by the upstream up-regulation of LOH2. 307 Since the increase of the turnover rate is not linked to metabolite concentration, the changes of (Table S2) , they have similar effects on sphingolipid metabolism. Our model also proposes a Last, to confirm the predictions of the model, we directly measured the in vivo flux change in 318 response to SA and BTH treatments. For SA and BTH treatments, the isotope incorporation rate 319 significantly increased for certain sphingolipid species such as LCBs and ceramides (Table 2) . 320 These results are consistent with our FBA model (Figure 2) . In a living cell, the synthesis and degradation of all substances occurs through metabolism. 392 However, current research tends to separate metabolites and functional molecules. The most 393 exciting aspect of plant sphingolipids is that they are themselves metabolites and functional 394 molecules. Our current model only deals with their metabolic properties in a self-balanced manner.
395
It will be interesting to incorporate the signaling network that involves sphingolipids to build an 396 integrated model to consider the direct effect of metabolism on cell signaling. In this study, we established a sphingolipid FBA model and used 15 N labeled isotopic transient 400 labeling to systematically explore the effects of SA and BTH on sphingolipid metabolic pathways.
401
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